Latest stories on CLYM
Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst
TipRanks63 · neutralproduct/pr
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility
Seeking Alpha73 · bullishproduct/pr
Climb Bio, Inc. (CLYM) files 8-K
SEC 8-K50 · neutralgeneral
Climb Bio Establishes New At-the-Market Equity Program
TipRanks28 · bearishgeneral
Climb Bio, Inc. (CLYM) files 8-K
SEC 8-K50 · neutralgeneral
Climb Bio Reports Encouraging Early Budoprutug ITP Data
TipRanks63 · neutralproduct/pr
Climb Bio, Inc. (CLYM) files 8-K
SEC 8-K50 · neutralgeneral
Climb Bio, Inc. (CLYM) files 8-K
SEC 8-K50 · neutralgeneral
Climb Bio Reports Positive Early-Stage Data for CLYM116
TipRanks63 · neutralproduct/pr
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 | CLYM Stock News
StockTitan56 · neutralproduct/pr
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing
Yahoo Top28 · bearishgeneral